Rhumbline Advisers Acelrx Pharmaceuticals Inc Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.03 - $1.7 $93,681 - $154,620	-90,953 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$1.25 - $2.77 $3,781 - $8,379	3,025 Added 3.44%	90,953 $155,000
Q4 2020 Feb 10, 2021	BUY	$1.18 - $1.98 $16,600 - $27,854	14,068 Added 19.05%	87,928 $109,000
Q3 2020 Nov 12, 2020	SELL	$1.01 - $1.81 $43,917 - $78,704	-43,483 Reduced 37.06%	73,860 $105,000
Q2 2020 Aug 13, 2020	BUY	$1.03 - $1.69 $6,566 - $10,773	6,375 Added 5.74%	117,343 $142,000
Q4 2019 Feb 05, 2020	BUY	$1.66 - $2.4 $2,146 - $3,103	1,293 Added 1.18%	110,968 $234,000
Q3 2019 Oct 23, 2019	BUY	$2.1 - $2.87 $19,265 - $26,329	9,174 Added 9.13%	109,675 $241,000
Q2 2019 Aug 14, 2019	BUY	$2.1 - $3.93 $211,052 - $394,968	100,501 New	100,501 $254,000

Ticker ACRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 7,366,600
Market Cap $8.32M
Description
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.